Nicolas Castillo’s Post

ESA HYPORESPONSIVENESS & CKD Patients exhibiting erythropoiesis-stimulating agent (ESA) hyporesponsiveness warrant referral to haematology for further evaluation of anaemia causes such as hemolysis and haemoglobinopathy. Diagnostic measures may include lactate dehydrogenase and haptoglobin levels, reticulocyte count, hemoglobin electrophoresis, and peripheral blood smear examination. As per KDOQI standards, ESA resistance or hyporesponsiveness is characterized by failure to attain target hemoglobin levels despite adequate iron stores and administration of epoetin at specified doses over 4–6 months. Potential causes encompass iron deficiency, vitamin B12 or folate deficiency, occult bleeding, hemolysis, chronic inflammation, inadequate dialysis, severe hyperparathyroidism, malignancy, bone marrow disorders, and haemoglobinopathies. Further exploration in this scenario should focus on investigating hemolysis and haemoglobinopathy, particularly indicated by microcytosis in the absence of iron deficiency. Collaborative efforts between haematology and nephrology are essential for comprehensive management. #AnemiaManagement #HematologyEvaluation #ESAResistance 🩸💊 https://lnkd.in/eAvDa8PT

We are pleased to announce that we have activated clinical sites and are initiating enrollment for the Phase 1 trial of ADI-001 in autoimmune diseases!   This follows the U.S. Food and Drug Administration’s (FDA) decision to grant Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV #lupus nephritis (LN) and clearance from FDA to develop ADI-001 in four #autoimmune indications including LN, systemic lupus erythematosus (#SLE), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV).   With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com. #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

For patients with FCS A study, which was presented at #ESC2024 discusses the effects of a drug called #plozasiran on patients with Familial Chylomicronemia Syndrome (#FCS), a rare genetic disorder leading to extremely high triglyceride levels, which increases the risk of acute pancreatitis. Key Findings: • Triglyceride Reduction: Plozasiran significantly lowered triglyceride levels by up to 80% compared to 17% in those receiving a placebo. • Pancreatitis Prevention: Patients treated with plozasiran had a reduced risk of pancreatitis, with fewer cases observed compared to the placebo group. • Safety: The drug was generally well-tolerated, with a safety profile similar to placebo, although some patients with diabetes experienced mild increases in blood sugar levels. •Importance for FCS Patients: Plozasiran offers a promising new treatment to manage dangerously high triglyceride levels and reduce the risk of pancreatitis, which is a serious and common complication for those with FCS. https://lnkd.in/eNsTwRgY Are you a person living with or caring for someone with #FCS? Would you like to connect with other patients across Europe for support, information exchange and advocacy purposes? If yes - contact us! #rarediseases #rarelipids #FCS Arrowhead Pharmaceuticals

New meta-analysis finds that half of psoriasis patients given placebo report adverse effects. 𝐒𝐨 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧? It means that researchers will have to consider the important of nocebo effects to "account for the observed adverse effects in patients who received placebo." This will be helpful for researchers conducting future studies regarding new treatments for patients with psoriasis. https://lnkd.in/g4_EbRDx

treated by a primary care physician in the past year was 5.9, with moderate severity accounting for 52% of the total cases. ・Among patients with moderate to severe disease, the percentage of EFT/FT and biological agents used was the highest for “immunoglobulin therapy” and “steroid pulse therapy” at an average of 35%, followed by “biological agents” at 24%. biological agents were used in approximately 20% of patients, regardless of whether they were seriously ill. *Early fast-acting treatment (EFT) ・Satisfaction rate (Top 2 box) for treatment of moderate or severe gMG remained at 16%. The reason for the low satisfaction level is thought to be that, although biological drugs have been added to the options, there are still patients who do not experience the effects. ・65% of physicians answered that the timing of using biological drugs was “after performing EFT/FT once or twice,” while 10% of physicians answered “before performing EFT/FT.” Regarding future usage policy, 31% of physicians answered “use it before performing EFT/FT.” ・It is expected that increasing the number of options for biological drugs and using them at an early stage, as well as providing treatments tailored to the severity of the disease, will lead to improvements in current dissatisfaction and treatment satisfaction. For more information on the survey results, please click here. URL：https://lnkd.in/gwPau69d Reference： https://lnkd.in/gA_7_9wV

The promising topline results from the Phase III PHOENYCS GO trial mark a potential turning point in the management of systemic lupus erythematosus, with dapirolizumab pegol emerging as a hopeful option for patients who often face a challenging and frustrating treatment landscape. Given that lupus disproportionately affects women and can lead to severe health complications, advancements in targeted therapies could greatly improve long-term outcomes and quality of life for this population. As the medical community continues to explore innovative approaches to manage autoimmune conditions, the potential for dapirolizumab pegol might usher in a new era of lupus care that prioritizes efficacy and patient-centered strategies. #LupusAwareness #AutoimmuneDisease #InnovativeTherapies #SLE #WomenHealth #DapirolizumabPegol

📣Pay attention folks!📣 A triple agonist medication for obesity and diabetes (currently there is only one dual-agonist available- Mounjaro) is now in phase II of clinical trials! #Retatrutide will most likely be available in a year. Dr. Alexander Williams told me to expect this years ago, and many other providers and pharmacists have been anticipating these new medications to help better treat patients. Looking at this trial data…the amount of fat that these medications can eliminate from the liver is extraordinary. Imagine the amount of heart and kidney disease (whether primary or secondary) that these medications will help prevent as well! Eli Lilly and Company #DiabetesMedications #GLP #GIP #Glucagon #ObesityMedications #WeightLossDrugs

Filsuvez is a newly approved topical drug to treat EB (epidermolysis bullosa). EB is a rare genetic disorder that causes fragile and painful blistering of the skin. In a recent study, placebo was shown to have equal to greater wound healing than Filsuvez. With not many treatment options available for EB, Filsuvez is a next step forward in discovering new treatments. How do you feel about paying for a drug when the treatment options are limited, but efficacy was similar to placebo and the cost per 23gm tube is $1,800?🤔 #Filsuvez #EB #epidermolysisbullosa #pharmacy #skinblistering #value Kara Webb LoneStar Health Solutions https://lnkd.in/gcardpSG

Over two decades, rheumatoid arthritis (RA) treatment options have advanced with drugs like MTX, bDMARDs, and tsDMARDs, notably improving patient management. Clinical evidence supports their efficacy in improving disease activity and joint prognosis, but long-term safety remains uncertain. This study analyzes the 10-year experience of the KURAMA cohort, examining treatment strategies and outcomes alongside therapeutic advances. Read more: https://lnkd.in/ducD6SGb #rheumatology #rheumatoidarthritis #treatment #therapeuticadvances #efficacy #concordbiotech

Dupilumab, when combined with antihistamines, has shown better results in treating chronic spontaneous urticaria (CSU) compared to using antihistamines alone. A recent study found that the addition of dupilumab to the treatment regimen led to improved outcomes for patients with CSU. This research suggests that a combination approach may be more effective in managing the symptoms of CSU. #CSU #treatment